There are currently 1372 clinical trials in Atlanta, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Emory University, Emory University Hospital, Children's Healthcare of Atlanta and Emory University Hospital/Winship Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm
NCT05027997
Recruiting
This study is designed to assess the safety and tolerability of dipraglurant in patients with blepharospasm (BSP) (randomized 1:1:1 to receive dipraglurant 50 mg, 100 mg or placebo) and explore the efficacy of 50 mg and 100 mg immediate release tablets (versus placebo) on the severity and frequency of BSP signs and symptoms using objective measures, clinical ratings and patient reported outcomes.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
11/01/2021
Locations: Emory University, Atlanta, Georgia
Conditions: Blepharospasm, Dystonia
Register for Updates
Intervention to Improve HIV Care Retention by Addressing Stigma Stigmatized Environments
NCT05110963
Recruiting
Retention in care and persistent adherence to antiretroviral therapy are necessary for the successful treatment of HIV infection. HIV-related stigma is a known impediment to the care and health outcomes of people living with HIV. The proposed study will test theory-based interventions designed to manage HIV stigma in order to improve care retention and medication adherence in communities with high-levels of HIV-related stigma.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/28/2021
Locations: University of Connecticut Field Site, Atlanta, Georgia
Conditions: HIV I Infection
Register for Updates
HIV Treatment Adherence Dose Determination Trial
NCT04577313
Recruiting
The proposed research will conduct the first dose-determination trial to find the optimal number of behavioral counseling sessions (dose) needed to achieve and sustain optimal HIV treatment adherence. The results of this study will determine how much intervention is needed for whom and at what cost to guide health policy and implementation of behavioral interventions designed to improve durable viral suppression.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/13/2021
Locations: University of Connecticut Field Site, Atlanta, Georgia
Conditions: HIV Infections
Register for Updates
Dietary Oxysterols and β-Cell Function Among African Americans
NCT05072587
Recruiting
African Americans (AAs) have a higher risk of developing type 2 diabetes than the general population. AAs are also more likely to eat foods that contain cholesterol oxides/oxysterols. Dietary oxysterols can harm the cells that produce insulin and decrease insulin production. This pilot study seeks to determine if removing dietary oxysterols with a plant-based diet will improve insulin production and decrease the risk of type 2 diabetes among AAs.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/08/2021
Locations: Morehouse School of Medicine, Atlanta, Georgia
Conditions: Type 2 Diabetes
Register for Updates
Continuous Monitoring and Control of Hypoglycemia
NCT03340831
Recruiting
Evaluate safety of non-adjunctive CGM use in CGM naive participants.
Gender:
All
Ages:
2 years and above
Trial Updated:
09/17/2021
Locations: Atlanta Diabetes, Atlanta, Georgia
Conditions: Diabetes
Register for Updates
Myeloma-Developing Regimens Using Genomics (MyDRUG)
NCT03732703
Recruiting
The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment arms. These arms have treatments specifically directed to the mutated genes. Patients that do not have a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/09/2021
Locations: Emory University, Atlanta, Georgia
Conditions: Relapsed Refractory Multiple Myeloma
Register for Updates
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
NCT03509961
Recruiting
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will be screened by NGS-MRD on a test of bone marrow done before the HCT. Subjects who are pre-HCT NGS-MRD negative will be eligible to receive a non-TBI conditioning regime... Read More
Gender:
All
Ages:
Between 1 year and 25 years
Trial Updated:
08/20/2021
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: B-cell Acute Lymphoblastic Leukemia
Register for Updates
Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder
NCT04948151
Recruiting
This study is looking to minimize side effects, while maintaining and potentially improving the therapeutic benefit to patients suffering from Female Sexual Arousal Disorder by providing a topical preparation of Sildenafil locally to the vulvar-vaginal tissue.
Gender:
Female
Ages:
21 years and above
Trial Updated:
06/24/2021
Locations: AGILE Clinical Research Trials, Atlanta, Georgia
Conditions: Female Sexual Arousal Disorder
Register for Updates
An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
NCT02633683
Recruiting
The objectives of the trial are to evaluate the long-term efficacy and safety of HORIZANT (Gabapentin Enacarbil) 600 mg daily, for the treatment of RLS in adolescents (13 to 17 years of age) diagnosed with moderate-to-severe primary RLS.
Gender:
All
Ages:
Between 13 years and 17 years
Trial Updated:
06/07/2021
Locations: Clinical Integrative Research Center of Atlanta, INC, Atlanta, Georgia
Conditions: RLS
Register for Updates
Evaluation of Medtronic DUO Extended Set
NCT04823312
Recruiting
This study is a single-center, non-randomized, prospective single arm study of adult subjects with type 1 diabetes utilizing 670G insulin pump therapy with Continuous Glucose Monitoring (CGM). These subjects will be using 4 DUO Extended sets that will serve as an exploratory pilot study to assess the 7-day survival of the Duo Extended set.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/29/2021
Locations: Atlanta Diabetes Associates, Atlanta, Georgia
Conditions: Diabetes Mellitus, Type 1
Register for Updates
Morehouse Total Cancer Care Protocol
NCT04804878
Recruiting
The overall objective of the Morehouse Total Cancer Care study is to develop an improved standard of cancer care by facilitating new biomarker and drug target discovery, informatics solutions, clinical trials, and "personalized medicine" for our community oncology partners (i.e., community hospital systems, and other cancer care providers). To bring new translational research to the community, Morehouse School of Medicine has initiated the Total Cancer Care Program (TCCP). The TCCP establishes a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/16/2021
Locations: Morehouse School of Medicine, Atlanta, Georgia
Conditions: Cancer, Cancer Risk
Register for Updates
Characterization of 3q29 Deletion Syndrome and 3q29 Duplication Syndrome
NCT02447861
Recruiting
The 3q29 deletion syndrome is caused by a deletion of a small part of human chromosome 3, and the duplication syndrome is caused by a duplication of this same small region. The purpose of this study is to understand the medical and behavioral consequences of these syndromes.
Gender:
All
Ages:
All
Trial Updated:
02/01/2021
Locations: Internet-Based, Atlanta, Georgia
Conditions: Microdeletion 3q29 Syndrome, Microduplication 3q29 Syndrome
Register for Updates